国际标准期刊号: 2329-9053

分子药剂学与有机过程研究杂志

开放获取

我们集团组织了 3000 多个全球系列会议 每年在美国、欧洲和美国举办的活动亚洲得到 1000 多个科学协会的支持 并出版了 700+ 开放获取期刊包含超过50000名知名人士、知名科学家担任编委会成员。

开放获取期刊获得更多读者和引用
700 种期刊 15,000,000 名读者 每份期刊 获得 25,000 多名读者

索引于
  • CAS 来源索引 (CASSI)
  • 哥白尼索引
  • 谷歌学术
  • 夏尔巴·罗密欧
  • 打开 J 门
  • 学术钥匙
  • 参考搜索
  • 哈姆达大学
  • 亚利桑那州EBSCO
  • OCLC-世界猫
  • 普布隆斯
  • 欧洲酒吧
  • ICMJE
分享此页面

抽象的

Academic Prespective on the Urgent COVID-19 Vaccine Research, Development and Delivery.

Reza Nassiri

 

Vaccine researchers and developers worldwide are intensely working toward a common global health goal to develop a safe and effective vaccine(s) protecting the global population fromSARS-CoV-2 (COVID-19; the WHO nomenclature).  An ideal vaccine profile must proveto be both effective and safe when administered in the general population.  To date, there arefew vaccine candidates that show optimistic grounds for clinical trials, and thus, the promise of a vaccine is on the horizon (https://clinicaltrials.gov). There is an accelerated effort worldwide to deliver such a promise, a global marathon to also gain the market share of vaccine delivery. The nucleic acid vaccines such as DNA or mRNA vaccines are new-generation gene vaccines.  Selection of a specific target as an antigenic determinant in the molecular structure of SARS-CoV-2 is the most important step in vaccine research and design. It can be packaged as a recombinant protein eliciting neutralizing antibody production. Accordingly, the precise conformation of the protein is consequential in humoral immune responses in which the spike protein plays a central role.

 This viral receptor binds to the host cells at least 10 times as tightly as has been reported for COVID-19.  Precise mapping of this protein is a critical step toward vaccine discovery because the spike protein is one essential element of the virus that the immune system can potentially identify as non-self.  Once the introduction of this step is established to the immune cells, such cells are likely to trigger an immune response and subsequent production of antibodies.